<DOC>
	<DOCNO>NCT00691236</DOCNO>
	<brief_summary>This trial pilot study find zoledronic acid improve response chemotherapy high grade osteosarcoma . In arm A study , 40 adult patient randomise two group . One group get standard chemotherapy group get Zoledronic acid addition chemotherapy . The investigator assess histological necrosis well disease status 2 year . In Arm B , adult patient relapse disease advanced disease unable take therapy give symptomatic care give 6 dos zoledronic acid follow disease status . This determine role zoledronic acid single agent .</brief_summary>
	<brief_title>Evaluation Zoledronic Acid Single Agent Adjuvant Chemotherapy High Grade Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Adult patient ( age 18 65 year ) recently diagnose high grade osteosarcoma extremity 2 . Non Metastatic presentation . The metastasis rule CT scan chest PET scan . 3 . Patients willing able afford standard chemotherapy . 1 . Nonextremity sarcoma . ( pelvis spine ) 2 . Age le 18 year great 65 year 3 . Metastatic presentation 4 . Pregnant lactate woman 5 . Renal dysfunction form elevate serum creatinine 6 . Dental treatment anticipated evaluation . 7 . Patients receive likely receive steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>adjuvant chemotherapy</keyword>
</DOC>